{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:22:55Z","timestamp":1787977375267,"version":"build-2784847793"},"reference-count":50,"publisher":"Royal College of Psychiatrists","issue":"3","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["GALENOS"],"award-info":[{"award-number":["GALENOS"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cambridge.org"],"crossmark-restriction":true},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec id=\"S000712502400237X_sec_a1\"><jats:title>Background<\/jats:title><jats:p>Trace amine-associated receptor 1 (TAAR1) agonists offer a new approach, but there is uncertainty regarding their effects, exact mechanism of action and potential role in treating psychosis.<\/jats:p><\/jats:sec><jats:sec id=\"S000712502400237X_sec_a2\"><jats:title>Aims<\/jats:title><jats:p>To evaluate the available evidence on TAAR1 agonists in psychosis, using triangulation of the output of living systematic reviews (LSRs) of animal and human studies, and provide recommendations for future research prioritisation.<\/jats:p><\/jats:sec><jats:sec id=\"S000712502400237X_sec_a3\" sec-type=\"methods\"><jats:title>Method<\/jats:title><jats:p>This study is part of GALENOS (Global Alliance for Living Evidence on aNxiety, depressiOn and pSychosis). In the triangulation process, a multidisciplinary group of experts, including those with lived experience, met and appraised the first co-produced living systematic reviews from GALENOS, on TAAR1 agonists.<\/jats:p><\/jats:sec><jats:sec id=\"S000712502400237X_sec_a4\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>The animal data suggested a potential antipsychotic effect, as TAAR1 agonists reduced locomotor activity induced by pro-psychotic drug treatment. Human studies showed few differences for ulotaront and ralmitaront compared with placebo in improving overall symptoms in adults with acute schizophrenia (four studies, <jats:italic>n<\/jats:italic> = 1291 participants, standardised mean difference (SMD) 0.15, 95% CI \u22120.05 to 0.34). Large placebo responses were seen in ulotaront phase three trials. Ralmitaront was less efficacious than risperidone (one study, <jats:italic>n<\/jats:italic> = 156 participants, SMD = \u22120.53, 95% CI \u22120.86 to \u22120.20). The side-effect profile of TAAR1 agonists was favourable compared with existing antipsychotics. Priorities for future studies included (a) using different animal models of psychosis with greater translational validity; (b) animal and human studies with wider outcomes including cognitive and affective symptoms and (c) mechanistic studies and investigations of other potential applications, such as adjunctive treatments and long-term outcomes. Recommendations for future iterations of the LSRs included (a) meta-analysis of individual human participant data, (b) including studies that used different methodologies and (c) assessing other disorders and symptoms.<\/jats:p><\/jats:sec><jats:sec id=\"S000712502400237X_sec_a5\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>This co-produced, international triangulation examined the available evidence and developed recommendations for future research and clinical applications for TAAR1 agonists in psychosis. Broader challenges included difficulties in assessing the risk of bias, reproducibility, translation and interpretability of animal models to clinical outcomes, and a lack of individual and clinical characteristics in the human data. The research will inform a separate, independent prioritisation process, led by lived experience experts, to prioritise directions for future research.<\/jats:p><\/jats:sec>","DOI":"10.1192\/bjp.2024.237","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T03:58:58Z","timestamp":1734926338000},"page":"162-170","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":14,"title":["Triangulating evidence from the GALENOS living systematic review on trace amine-associated receptor 1 (TAAR1) agonists in psychosis"],"prefix":"10.1192","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2679-1472","authenticated-orcid":false,"given":"Katharine A.","family":"Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8643-3250","authenticated-orcid":false,"given":"Niall","family":"Boyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0852-4322","authenticated-orcid":false,"given":"Astrid","family":"Chevance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6196-3308","authenticated-orcid":false,"given":"Virginia","family":"Chiocchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7316-1716","authenticated-orcid":false,"given":"Kim","family":"Donoghue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikita","family":"Ghodke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatenda","family":"Kambeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-9091","authenticated-orcid":false,"given":"Gin S.","family":"Malhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9187-9839","authenticated-orcid":false,"given":"Malcolm","family":"Macleod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7865-5533","authenticated-orcid":false,"given":"Lea","family":"Milligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Potts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma S. J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8264-2039","authenticated-orcid":false,"given":"Spyridon","family":"Siafis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris E. C.","family":"Sommer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Voelkl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-8508","authenticated-orcid":false,"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-8321","authenticated-orcid":false,"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian P. T.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"170","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"S000712502400237X_ref8","first-page":"1866","article-title":"Triangulation in aetiological epidemiology","volume":"45","author":"Lawlor","year":"2016","journal-title":"Int J Epidemiol"},{"key":"S000712502400237X_ref20","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.19866.1"},{"key":"S000712502400237X_ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-02138-4"},{"key":"S000712502400237X_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01997-8"},{"key":"S000712502400237X_ref2","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21056"},{"key":"S000712502400237X_ref9","doi-asserted-by":"publisher","DOI":"10.1086\/684960"},{"key":"S000712502400237X_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.05.008"},{"key":"S000712502400237X_ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-022-06030-2"},{"key":"S000712502400237X_ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2021.08.005"},{"key":"S000712502400237X_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"S000712502400237X_ref1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2147342"},{"key":"S000712502400237X_ref47","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.0624"},{"key":"S000712502400237X_ref19","article-title":"Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and metaanalysis of human and non-human studies","author":"Siafis","year":"2024","journal-title":"Open Sci Framework"},{"key":"S000712502400237X_ref42","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.62.9.975"},{"key":"S000712502400237X_ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02638-x"},{"key":"S000712502400237X_ref50","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a040659"},{"key":"S000712502400237X_ref31","unstructured":"31 Hoffmann-La Roche, F. Hoffmann-La Roche: NCT04512066: A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients with an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder. F. Hoffmann-La Roche, 2022 (https:\/\/cdn.clinicaltrials.gov\/large-docs\/66\/NCT04512066\/SAP_001.pdf)."},{"key":"S000712502400237X_ref23","first-page":"460","article-title":"The NIH consensus development program: the evolution of guidelines","volume":"12","author":"Ferguson","year":"1996","journal-title":"Int J Technol Assess Health Care"},{"key":"S000712502400237X_ref32","first-page":"77","article-title":"Positive and negative syndrome scale (PANSS) training: challenges, solutions, and future directions","volume":"14","author":"Opler","year":"2017","journal-title":"Innov Clin Neurosci"},{"key":"S000712502400237X_ref18","doi-asserted-by":"publisher","DOI":"10.12688\/wellcomeopenres.21302.1"},{"key":"S000712502400237X_ref43","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20822"},{"key":"S000712502400237X_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S2215-0366(17)30270-5"},{"key":"S000712502400237X_ref36","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-22-0330"},{"key":"S000712502400237X_ref44","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2024.0178"},{"key":"S000712502400237X_ref16","first-page":"448","article-title":"Treatment resistance in schizophrenia: a meta-analysis of prevalence and correlates","volume":"45","author":"Diniz","year":"2023","journal-title":"Braz J Psychiatry"},{"key":"S000712502400237X_ref27","unstructured":"27 Morley, R , Gilbert, D , for the GALENOS Work Package 1 Team. GALENOS Involvement of People with Lived Experience in Living Systematic Reviews. GALENOS, 2023 (https:\/\/galenos.ams3.digitaloceanspaces.com\/060b6fa304ea0644fa73e7f16ae6b94e.pdf)."},{"key":"S000712502400237X_ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-013-0067-9"},{"key":"S000712502400237X_ref35","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"S000712502400237X_ref26","doi-asserted-by":"publisher","DOI":"10.2196\/57155"},{"key":"S000712502400237X_ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413185"},{"key":"S000712502400237X_ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911772"},{"key":"S000712502400237X_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2022.10.010"},{"key":"S000712502400237X_ref37","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023)","author":"Higgins","year":"2023"},{"key":"S000712502400237X_ref28","article-title":"GRIPP2 reporting checklists: tools to improve reporting of patient and public involvement in research","volume":"358","author":"Staniszewska","year":"2017","journal-title":"BMJ"},{"key":"S000712502400237X_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.08.010"},{"key":"S000712502400237X_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/bjps\/axw008"},{"key":"S000712502400237X_ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300759"},{"key":"S000712502400237X_ref24","volume-title":"WHO Handbook for Guideline Development","year":"2014"},{"key":"S000712502400237X_ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2021.06.024"},{"key":"S000712502400237X_ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD"},{"key":"S000712502400237X_ref40","article-title":"Publication rate in preclinical research: a plea for preregistration","volume":"4","author":"Van der Naald","year":"2020","journal-title":"BMJ Open Sci"},{"key":"S000712502400237X_ref45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2021.05.025"},{"key":"S000712502400237X_ref29","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 6.4 (Updated August 2023)","author":"Sch\u00fcnemann","year":"2023"},{"key":"S000712502400237X_ref49","doi-asserted-by":"publisher","DOI":"10.1192\/bjb.2021.51"},{"key":"S000712502400237X_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.10.014"},{"key":"S000712502400237X_ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmjment-2023-300670"},{"key":"S000712502400237X_ref7","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-018-01023-3"},{"key":"S000712502400237X_ref39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjos-2021-100219"},{"key":"S000712502400237X_ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-023-01949-9"},{"key":"S000712502400237X_ref22","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15197"}],"container-title":["The British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S000712502400237X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T12:35:02Z","timestamp":1742906102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S000712502400237X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S000712502400237X"],"URL":"https:\/\/doi.org\/10.1192\/bjp.2024.237","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,23]]},"assertion":[{"value":"\u00a9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists","name":"copyright","label":"Copyright","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http:\/\/creativecommons.org\/licenses\/by\/4.0\/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}